Danazol therapy for chronic immune-mediated thrombocytopenic purpura in a patient with common variable immunodeficiency.
We describe a patient with common variable immunodeficiency (CVI) and chronic immune-mediated thrombocytopenic purpura (ITP), refractory to treatment with corticosteroids, splenectomy, and intravenous immunoglobulin. He had a prompt response to danazol, and the platelet counts have been maintained in the normal range with low-dose, alternate-day, danazol therapy. This case provides evidence that danazol is effective in the treatment of chronic ITP in patients with immunodeficiency and indicates that some patients can be maintained on an alternate-day regimen.
Saulsbury
F T
FT
Department of Pediatrics, University of Virginia Health Sciences Center, Charlottesville 22908.
Bringelsen
K A
KA
D000328:Adult; D003131:Combined Modality Therapy; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008297:Male; D010976:Platelet Count / Q000187:drug effects; D011241:Prednisone / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000601:surgery / Q000628:therapy; D013156:Splenectomy
D016756:Immunoglobulins, Intravenous; D003613:Danazol; D011241:Prednisone